Still Enriched By Partnership, Curis Faces Ongoing Risks In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
The Lexington, Mass.-based oncology specialist seeks to resume enrollment in a Phase I trial halted after a patient death, while a revenue-generating drug partnered with Genentech could soon have a new competitor.